Vericel (NASDAQ:VCEL) Stock Rating Upgraded by Wall Street Zen

Vericel (NASDAQ:VCEL) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

A number of other research firms also recently weighed in on VCEL. Leerink Partners reaffirmed an “outperform” rating and set a $46.00 price target on shares of Vericel in a research note on Tuesday, March 10th. HC Wainwright raised their price objective on Vericel from $60.00 to $64.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Truist Financial decreased their price objective on Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Vericel Stock Performance

NASDAQ:VCEL opened at $29.34 on Friday. Vericel has a 12 month low of $28.95 and a 12 month high of $46.10. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 94.65 and a beta of 1.22. The firm has a fifty day simple moving average of $35.17 and a two-hundred day simple moving average of $35.79.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share for the quarter, meeting the consensus estimate of $0.45. The firm had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. Vericel had a net margin of 5.98% and a return on equity of 5.17%. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.38 earnings per share. Equities analysts predict that Vericel will post 0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vericel

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in Vericel during the 4th quarter valued at about $27,000. Huntington National Bank raised its stake in shares of Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 273 shares during the last quarter. Quarry LP bought a new position in shares of Vericel in the fourth quarter valued at approximately $31,000. Farther Finance Advisors LLC lifted its holdings in shares of Vericel by 116.5% in the fourth quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 522 shares in the last quarter. Finally, Abich Financial Wealth Management LLC bought a new position in shares of Vericel in the third quarter valued at approximately $31,000.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.